MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents.
Fan W, Tang Z, Yin L, Morrison B, Hafez-Khayyata S, Fu P, Huang H, Bagai R, Jiang S, Kresak A, Howell S, Vasanji A, Flask CA, Halmos B, Koon H, Ma PC.
Fan W, et al. Among authors: huang h.
Cancer Res. 2011 Jul 1;71(13):4494-505. doi: 10.1158/0008-5472.CAN-10-2668. Epub 2011 May 9.
Cancer Res. 2011.
PMID: 21555370
Free PMC article.